Kennedy Capital Management’s Aldeyra Therapeutics ALDX Stock Holding History

Kennedy Capital Management’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$162K	Sell	95,862 -1,159,976	-92%	-$5.08M	﹤0.01%	535
2025 Q4	$6.51M	Buy	1,255,838 +143,625	+13%	+$738K	0.14%	243
2025 Q3	$5.81M	Buy	1,112,213 +425,245	+62%	+$2.22M	0.13%	268
2025 Q2	$2.63M	Sell	686,968 -546,446	-44%	-$1.41M	0.06%	398
2025 Q1	$7.09M	Sell	1,233,414 -235,105	-16%	-$1.39M	0.17%	212
2024 Q4	$7.33M	Sell	1,468,519 -412,559	-22%	-$2.12M	0.16%	218
2024 Q3	$10.1M	Buy	1,881,078 +281,405	+18%	+$1.34M	0.22%	138
2024 Q2	$5.29M	Buy	1,599,673 +281,518	+21%	+$1.1M	0.11%	306
2024 Q1	$4.31M	Buy	1,318,155 +42,009	+3%	+$138K	0.09%	355
2023 Q4	$4.48M	Buy	+1,276,146	New	+$3.94M	0.1%	325

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Kennedy Capital Management's ALDX Position: Q1 2026 in Review

Kennedy Capital Management reduced its Aldeyra Therapeutics (ALDX) stake by 92% in Q1 2026, selling an estimated $5.08M and leaving 95,862 shares worth $162K. The position accounts for ﹤0.01% of the portfolio, ranked #535.

Kennedy Capital Management first reported a position in ALDX in Q4 2023 and has held it in 10 quarters since. The position peaked at $10.1M in Q3 2024. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

Kennedy Capital Management held 95,862 shares of Aldeyra Therapeutics worth $162K as of Q1 2026.
Kennedy Capital Management sold 1,159,976 Aldeyra Therapeutics shares in Q1 2026, an estimated $5.08M.
Aldeyra Therapeutics made up ﹤0.01% of Kennedy Capital Management's portfolio in Q1 2026, its #535 holding.
Kennedy Capital Management first reported a position in Aldeyra Therapeutics in Q4 2023 and has held it in 10 quarters since.
Kennedy Capital Management's Aldeyra Therapeutics position peaked at $10.1M in Q3 2024.
126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Kennedy Capital Management's 13F filing for Q1 2026, filed 13 May 2026.